Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
Forthcoming
Status as published by the data source.
Expected Outcome:
This action supports the follow-up to the July 2023 Communication on EU Missions assessment[1]. Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:
• Public procurers, possibly in cooperation with private ones, in the area of cancer-centred healthcare stimulate the competitive development of market-ready, affordable, innovative solutions.
• The chosen solutions take into consideration the needs of cancer patients living with and beyond cancer through research that supports end-user engagement using participative research models.
• Procurers create opportunities for European health, technology and medical devices, industrial actors (including start-ups, spin-offs, spin-outs, scale-ups, SMEs) to bring to the market affordable innovations that are cost-efficient, safe and have demonstrated improved health outcomes for cancer patients living with and beyond cancer.
• Procurers facilitate the commercialisation of innovative solutions for and with cancer patients by their successful suppliers through providing them with first customer references for the validation and first pilot deployment.
• Policymakers, healthcare providers and professionals, cancer patients and their carers – each in their respective areas – exchange and adopt good practices and the best treatment, technology and medical device solutions that the market can deliver through participative research. Scope:
Pre-commercial procurement (PCP) actions target consortia of procurers with similar needs that want to procure together the development of affordable, innovative solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines[2].
Proposals should address all of the following:
• The focus should be on affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines that benefit cancer patients. Within this topic, it is possible to foresee the transfer and adaptation of solutions and/or interventions from other sectors to healthcare systems. It is open both to proposals requiring improvements based on one specific solution or technology, or medical device as well as to proposals requiring end-to-end solutions that need combinations of different types of innovation.
• The requested innovative solutions for healthcare systems in the areas of affordable cancer technologies, cancer medical devices, or cancer medicines should be clinically validated, piloted or upscaled by the participating procurers in at least five different countries across the EU Member States and Associated Countries.
• Continuous dialogue between the demand and supply side is required for the success of pre-commercial procurement. Therefore the effective involvement of end-users (e.g. academia, clinical teams, cancer patients and their caregivers/families, cancer patient representatives, local or regional medical services, hospitals, production facilities) must be considered in the proposal. To stimulate dialogue with the supply side, procurers are required to organise an open-market consultation before launching the procurement and to promote the call for tenders widely across Europe to potentially interested suppliers.
• Procurers should declare in the proposal their interest to purchase at least one solution resulting from the PCP in case the PCP delivers successful solutions and indicate whether they will (1) procure the solution(s) as part of the PCP or (2) in a separate follow-up procurement after the PCP. In the first case, procurers can implement the project as a fast-track PCP (see general annex H) and foresee the budget to purchase at least one solution during the PCP. In the second case, the procurers must include in the proposal a deliverable that prepares the follow-up procurement to purchase successful solution(s) after the PCP.
• Activities covered should support national healthcare systems and mobilise technical assistance and/or capacity building to other procurers beyond the project to mainstream PCP implementation and to remove obstacles for introducing the innovative solutions for the benefit of cancer patients to be procured into the market. [1] EUR-Lex - 52023DC0457 - EN - EUR-Lex
[2] Pre-commercial procurement (PCP) actions target consortia of procurers with similar needs that want to procure together the development of affordable, innovative solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines. This topic does not provide direct funding to developers, industry or research organisations to perform R&D. They will be able to respond to the call for tenders launched by consortia of procurers funded under this call
- Status
- Forthcoming
- Deadline
- (time not stated)
- Opens
- Published
- Total budget
- €26,000,000
- Grant range
- €8,000,000 – €10,000,000
- Country
- European Union (EU-wide)
- Programme
- Horizon Europe (HORIZON)
- Official page
- Open at the source portal
Other calls under Horizon Europe (HORIZON)
- PV based electrification of the economy: Designing & optimising PV systems supporting industrial electrification and promoting participation in electricity markets (EUPI-PV Partnership)
- Advanced TSO control rooms to enhance grid observability, stability and resilience
- Advanced Distribution Management Systems (ADSM) for more efficient and flexible distribution grids
- Community of practice - Data-Driven Decision-Making in Energy
- Industrial processes and equipment for innovative, reliable and scalable tandem technologies (EUPI-PV Partnership)
- Integrated Approaches for Retrofitting Infrastructures with Innovative Energy Storage Technologies
- Demonstration of hydropower technologies for efficient and forward-looking refurbishment of existing hydropower plants
- Delivery of industrial CCUS clusters – Societal Readiness pilot
All calls under this programme
Similar opportunities
- Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
- Open grounds for future pre-commercial procurement of innovative security technologies
- Earlier and more precise palliative care
- Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
- Boosting the transformation towards climate-neutral cities, the net-zero economy and open strategic autonomy through Pre-Commercial Procurement (PCP)
Where this came from
- Source document
- https://ec.europa.eu/info/funding-tenders/opportunities/data/topicDetails/horizon-miss-2027-02-cancer-05.json
- Document fingerprint
ff2163eb67acebe9(SHA-256, first 16 hex characters)- Retrieved
- First recorded here
What has changed
- url first recorded as https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-miss-2027-02-cancer-05 on
- currency first recorded as EUR on
- amount_max first recorded as 10000000.00 on
- amount_min first recorded as 8000000.00 on
- budget_total first recorded as 26000000.00 on
- deadline first recorded as 2027-09-21 on
- opens_on first recorded as 2027-02-10 on
- published_on first recorded as 2025-12-12 on
- status_basis first recorded as source_status on
- status first recorded as forthcoming on
- title first recorded as Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines on
Data source
© European Union, 2026. Source: EU Funding & Tenders Portal. Reused under Commission Decision 2011/833/EU — CC BY 4.0.
Retrieved from the source on .
The source last updated this document on Mon, 06 Jul 2026 14:29:38 GMT.
Personal data of natural persons has been dissociated by quiescence.eu.
This service is not affiliated with, sponsored or endorsed by the data publishers.